NDAORALCAPSULE, DELAYED RELEASE
Approved
Aug 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ESOMEPRAZOLE STRONTIUM (esomeprazole strontium) by R-Pharm US is 12. First approved in 2013.
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Esomeprazole strontium is an oral delayed-release proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting H+/K+-ATPase in gastric parietal cells. It is used to treat gastroesophageal reflux disease (GERD) and other acid-related disorders by blocking the final step of acid production. The S-isomer active form is generated in the acidic parietal cell compartment, providing dose-dependent acid suppression up to 20–40 mg daily.
Peak
Product is in peak commercial phase with moderate competitive pressure (30% score), indicating stable market presence and likely full-strength commercial infrastructure.
Mechanism of Action
12.CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H /K -ATPase in the gastric parietal cell. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the…
Worked on ESOMEPRAZOLE STRONTIUM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.